CRISPR Therapeutics and ViaCyte, Inc. have received the green light from Health Canada for their Clinical Trial Application for VCTX210: an allogeneic, gene-edited, immune-evasive, stem cell-derived therapy for the treatment of type 1 diabetes (T1D)....
Lonza enters private label partnership to manufacture and globally commercialize AllCell’s hematopoietic primary cells to provide greater access to researchers.
Plasticell has teamed with Anthony Nolan to access the latter’s cord-blood bank and boost patient recruitment for its allogeneic haematopoietic stem cell transplantation (HSCT) therapy trials.
Ncardia is ‘moving up the value chain’ as it shifts from a product-focused company to a preclinical contract research organization (CRO) and grows in size – and clout, says VP.
Ncardia has entered into a non-exclusive licensing agreement with Evotec through which the drug discovery solutions company will gain access to Ncardia’s stem cell derived cellular disease modeling IP.
Evotec is collaborating with academic institutions to develop a device to test drug candidates in the kidney, which it says could improve and accelerate clinical trials.
The US FDA has warned a Florida-based clinic and seized vials of a smallpox vaccine in California used to create an unapproved product in a crackdown against "unscrupulous" stem cell firms.
Evotec and Fraunhofer IME-SP have signed a strategic collaboration to advance Evotec’s patient-derived iPSC platform and subsequent drug discovery projects.
Manufacturing tweaks have severe effects on the quality and yield of stem cells, says Pluristem which has successfully scaled-up production through a decade of process development evolution.
Sumitomo Dainippon Pharma Co Ltd has ordered cell culture technologies from Hitachi as part of its effort to develop a treatment for Parkinson’s disease.
Merck KGaA has partnered up with clinical research organisation (CRO) Evotec Ag to serve as a one-stop shop for new target discovery using its gene-editing reagents.
As stem cell and gene editing technologies become more advanced, researchers are increasingly interested in growing human tissues and organs in animals – but what are the implications of human-animal chimeras?
Researchers supported by the National Institutes of Health (NIH) have developed a clinical-grade stem cell line, which will help accelerate early-stage clinical research.
BioLife Solutions has partnered with transportation firm MNX and says it expects increased demand for its biologistics services as more cell therapies enter the clinic.
While there are currently several techniques for producing tissue from heart cells, a new method reduces the amount of cells needed, making it easier and cheaper to replicate.
Regenerative medicine developers now have a new supplier for mesenchymal stem cells (MSCs), the multipotent stromal cells derived from marrow and other tissues like muscle and dental pulp for tissue repair.
Reneuron has been granted a US patent for a cryopreservation technology that does not rely on toxic reagents and says it would consider licensing it to other stem cell therapy developers on a case-by-case basis.
Biocision has revamped its cell thawing platform to accommodate larger vial sizes and started developing an automated system for cell therapies in cryopreservation bags.
Preclinical CRO Biopta will add stem cell programming tech to its offering, expand in Japan and nearly double its workforce under new owner, Reprocell.
Lonza has published a guide to clinical-grade induced pluripotent stem cell (IPSC) manufacture, addressing concerns around the derivation of cellular materials.
Hamburg, Germany-based Evotec and Sanofi are launching a strategic collaboration in diabetes drug development that could be worth as much as $330m (€303m) for the German company, including €3m upfront.
Stem Cell Theranostics has secured rights to the technology it uses to make cellular heart disease models for drug development through a deal with GE Healthcare.
German-based contract manufacturer apceth has received regulatory approval to use two new GMP cleanrooms for aseptic processing, which will be used for the handling and genetic manipulation of various types of cell and gene therapies.
Making sure candidate drugs are free of cardiac risks means drug industry demand for ion channel screening expertise is growing according to new CRO, Metrion.
Under the partnership, Nikon will have access to Lonza’s quality and operating systems, facility design and ongoing consulting services for the establishment of a wholly-owned Nikon cell and gene therapy contract manufacturing business.
Sourcing human beta cells may soon no longer be a challenge for AstraZeneca diabetes researchers thanks to a new partnership with stem cell scientists at Harvard University.
Analyst firm N+1Singer has endorsed stem cell manufacturer Reneuron based on its “off-the-shelf” therapy pipeline and a new facility that will reduce the need to outsource.
A German biobank has made stem cells available to active pharmaceutical ingredient (API) firms this week in a bid to support industry drug development efforts.
Lonza has launched a new stem cell reprogramming and maintenance system that has already been used to support US NIH and pharmaceutical company preclinical drug development projects.
A new cell therapy development centre has opened at Guy’s Hospital in London today in the latest stage of a Government-backed effort to establish the UK as a global hub.
ScinoPharm Taiwan on Monday signed a manufacturing and clinical supply contract with TaiGen Biotechnology to provide the API for Burixafor, a potential stem cell treatment.
Tokyo, Japan-based JCR Pharmaceuticals has asked UK firm Plasticell to help develop differentiation protocols for its range of candidate stem cell-based therapies.
Good news for stem cell scientists this week with new data indicating that patients support the use of induced pluripotent stem cells (iPSC) in biopharmaceutical research if proper consent is obtained.
Duke University will play contract research organisation (CRO) for clinical trials of a Parkinson’s disease treatment being developed by International Stem Cell Corp (ISCO).
The California Institute of Regenerative Medicine’s board signed off on the allocation of $70M to begin setting up clinics and to bring a number of developing stem cell therapies into clinical trials.
Progenitor Cell Therapy (PCT) has started testing to see if an RNA-based characterization tech developed by Sistemic can improve cell therapy production.
GE Healthcare says new cell science lab in Wales will save drugmakers time and money and create more accurate alternatives to animal-based drug toxicity testing models.
